CS McKee’s Anika Therapeutics ANIK Stock Holding History

CS McKee’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$975K	Buy	18,810 +1,860	+11%	+$108K	0.09%	85
2019 Q3	$930K	Hold	16,950	–	–	0.08%	85
2019 Q2	$689K	Sell	16,950 -1,400	-8%	-$51K	0.06%	89
2019 Q1	$555K	Sell	18,350 -150	-0.8%	-$5.14K	0.05%	97
2018 Q4	$622K	Hold	18,500	–	–	0.06%	94
2018 Q3	$780K	Hold	18,500	–	–	0.06%	100
2018 Q2	$592K	Sell	18,500 -1,000	-5%	-$41.2K	0.05%	103
2018 Q1	$970K	Sell	19,500 -700	-3%	-$39.5K	0.08%	97
2017 Q4	$1.09M	Buy	20,200 +100	+0.5%	+$5.54K	0.08%	92
2017 Q3	$1.17M	Buy	20,100 +6,000	+43%	+$314K	0.09%	85
2017 Q2	$696K	Buy	14,100 +100	+0.7%	+$4.61K	0.06%	97
2017 Q1	$608K	Sell	14,000 -100	-0.7%	-$4.77K	0.05%	93
2016 Q4	$690K	Sell	14,100 -1,300	-8%	-$60.1K	0.05%	95
2016 Q3	$737K	Sell	15,400 -1,850	-11%	-$91.4K	0.05%	94
2016 Q2	$925K	Sell	17,250 -20,840	-55%	-$982K	0.04%	91
2016 Q1	$1.7M	Buy	+38,090	New	+$1.55M	0.06%	88

Other funds holding ANIK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

CS McKee's ANIK Position: Q4 2019 in Review

CS McKee increased its Anika Therapeutics (ANIK) stake by 11% in Q4 2019, buying an estimated $108K and bringing the position to 18,810 shares worth $975K. The position accounts for 0.09% of the portfolio, ranked #85.

CS McKee first reported a position in ANIK in Q1 2016 and has held it in 16 quarters since. The position peaked at $1.7M in Q1 2016. 191 funds tracked by Wall St. Rank hold ANIK as of Q4 2019.

CS McKee held 18,810 shares of Anika Therapeutics worth $975K as of Q4 2019.
CS McKee bought 1,860 Anika Therapeutics shares in Q4 2019, an estimated $108K.
Anika Therapeutics made up 0.09% of CS McKee's portfolio in Q4 2019, its #85 holding.
CS McKee first reported a position in Anika Therapeutics in Q1 2016 and has held it in 16 quarters since.
CS McKee's Anika Therapeutics position peaked at $1.7M in Q1 2016.
191 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2019.

Based on CS McKee's 13F filing for Q4 2019, filed 14 Feb 2020.